Verzenios ® ▼ (abemaciclib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Verzenios Summary of Product Characteristics (SmPC)

Are Verzenios® ▼ (abemaciclib) patients at an increased risk of experiencing venous thromboembolic events?

Venous thromboembolic events (VTEs) occurred in more patients who took abemaciclib than in patients who received placebo in the phase 3 studies for metastatic breast cancer.

UK_cFAQ_ABE045_VTE
UK_cFAQ_ABE045_VTE
en-GB

Detailed Information about VTEs in MONARCH 2 and MONARCH 3

VTEs have been identified as an adverse drug reaction for abemaciclib. This includes

  • deep vein thrombosis
  • pulmonary embolism
  • pelvic venous thrombosis
  • cerebral venous sinus thrombosis
  • subclavian and axillary vein thrombosis, and
  • inferior vena cava thrombosis.

Across the clinical development program, deaths due to VTEs have been reported.1

Most events were

  • considered non-serious
  • treated with low molecular weight heparin, and
  • not resulting in discontinuation of abemaciclib.

Risk factors for VTEs were balanced between study arms and overall, there were no specific risk factors identified that could predict VTEs with abemaciclib treatment.1

Please find the breakdown of VTEs in the phase 3 studies presented in VTEs in MONARCH 2 and MONARCH 3.

VTEs in MONARCH 2 and MONARCH 31,2

Event, n (%)

MONARCH 2

MONARCH 3

Abemaciclib + Fulvestrant
N=441

Placebo + Fulvestrant
N=223

Abemaciclib + NSAI
N=327

Placebo + NSAI
N=161

VTE (all grade)

21 (4.8)

2 (0.9)

20 (6.1)

1 (0.6)

PE

11 (2.5)

0

11 (3.4)a

1 (0.6)

DVT

10 (2.3)

2 (0.9)

9 (2.8)

0

Grade ≥3

9 (2.0)

1 (0.4)

10 (3.0)

1 (0.6)

Death

0

0

3 (0.9)b

0

SAE

8 (1.8)c

1 (0.4)

9 (2.8)

1 (0.6)

DC (all events)

2 (0.5)

0

4 (1.2)d

0

Dose reduction

2 (0.5)

0

0

1 (0.6)

Abbreviations: DC = discontinuation; DVT = deep vein thrombosis; NSAI = nonsteroidal aromatase inhibitor; PE = pulmonary embolism; SAE = serious adverse event; VTE(s) = venous thromboembolic event(s).

aThree patients experienced both PE and DVT.

bPE and DVT; Thromboembolism not further investigated; Respiratory failure.

c4 PE and 4 DVT.

dIncludes 3 patients who died.

References

1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2Rugo HS, Huober J, Llombart-Cussac A, et al. Management of abemaciclib associated adverse events in patients with HR+, HER2- advanced breast cancer: analysis of the MONARCH trials. Poster presented at: Annual Meeting of the European Society for Medical Oncology (ESMO) European Cancer Congress (ECC); October 19-23, 2018; Munich, Germany. https://www.esmo.org/content/download/149891/2691140/file/EMSO-2018-Abstract-Book-partial-version.pdf

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: January 28, 2020


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request